drugset / Trial / NCT05856747

A Study to Compare Two Bioanalytical Assays for Tebipenem

NCT05856747

Phase 1 Completed 20 enrolled Spero Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to compare the concentrations of tebipenem (TBP), the active moiety of tebipenem pivoxil hydrobromide (TBP-PI-HBr), as determined by two bioanalytical assays, a whole blood assay and a plasma assay, following a single oral dose of TBP-PI-HBr 600 milligram (mg) tablets in healthy adult participants.

Timeline

Start
2023-05-04
Primary completion
2023-06-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TBP-PI-HBr Unknown 600 mg Oral

Indications

No indication recorded.